NASDAQ:ICCM IceCure Medical Q4 2025 Earnings Results & Report $1.10 -0.03 (-2.65%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.14 +0.04 (+4.09%) As of 10/9/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. IceCure Medical reported Q4 2025 earnings on February 15, 2026. The company reported EPS of $1.80, while revenue was $1.28 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateFebruary 15, 2026TimeBefore Market Opens IceCure Medical EPS ResultsActual EPS$1.80Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersIceCure Medical Revenue ResultsActual Revenue$1.28 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsIceCure Medical's Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules, with a conference call scheduled at 10:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile IceCure Medical Q4 2025 Earnings FAQ Did IceCure Medical beat earnings estimates for Q4 2025? IceCure Medical (NASDAQ:ICCM) reported earnings of $1.80 per share for Q4 2025. The report was announced on Sunday, February 15, 2026. What was IceCure Medical's revenue for Q4 2025? IceCure Medical reported revenue of $1.28 million for Q4 2025. When is IceCure Medical's next earnings date? IceCure Medical's next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for IceCure Medical on the company's earnings history page. IceCure Medical Earnings HeadlinesIceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical SiteOctober 6, 2026 | prnewswire.comHead to Head Analysis: Zimmer Biomet (NYSE:ZBH) & IceCure Medical (NASDAQ:ICCM)October 6, 2026 | americanbankingnews.comThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.October 10 at 1:00 AM | Traders Agency (Ad)IceCure Medical Updates Board Plans and Agenda Ahead of November 2026 Shareholder MeetingOctober 5, 2026 | tipranks.comIceCure Medical Ltd. (NASDAQ:ICCM) Stock Has Consensus Target Price of $52.50 According to AnalystsOctober 1, 2026 | americanbankingnews.comContrasting IceCure Medical (NASDAQ:ICCM) & West Pharmaceutical Services (NYSE:WST)October 1, 2026 | americanbankingnews.comSee More IceCure Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IceCure Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IceCure Medical and other key companies, straight to your email. Email Address About IceCure MedicalIceCure Medical (NASDAQ:ICCM) (NASDAQ: ICCM) is an Israel-based medical technology company that develops minimally invasive cryoablation systems for the treatment of tumors. Its technology uses liquid nitrogen to freeze and destroy targeted tissue, with the goal of providing an alternative to surgical removal in selected patients. The company’s primary product is the ProSense system, which is designed to deliver controlled cryoablation through a probe inserted into a tumor. IceCure has focused on applications in breast, kidney, lung, and other solid tumors, including procedures performed under image guidance. The system and its related technologies are subject to regulatory clearances and approvals that vary by country and by intended use. IceCure was founded in Israel and serves healthcare providers and medical markets internationally. The company has supported clinical studies and commercial activities in the United States, Israel, Europe, and other regions as it seeks to expand the use of cryoablation in oncology. Its shares began trading on the Nasdaq Capital Market in 2021.View IceCure Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
